**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (original) A compound of formula (I) or pharmaceutically acceptable salts thereof:



(I)

wherein

$R^{F1}$ and $R^{F2}$ are independently electron-withdrawing groups;

Z is selected from O= and S=;

$R^1$ is selected from $C_{1-10}$ alkyl; $C_{1-10}$alkyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkenyl; $C_{2-10}$alkenyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkynyl; $C_{2-10}$alkynyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $R^3R^4N$-$C_{1-6}$alkyl; $R^3R^4NC(=O)$-$C_{1-6}$alkyl; $R^3O$-$C_{1-6}$ alkyl; $R^3OC(=O)$-$C_{1-6}$alkyl; $R^3C(=O)$-$C_{1-6}$alkyl; $R^3C(=O)NR^3$-$C_{1-6}$alkyl; $R^3R^4NSO_2$-$C_{1-6}$alkyl; $R^3CSO_2N(R^4)$-$C_{1-6}$alkyl; $R^3R^4NC(=O)N(R^5)$-$C_{1-6}$alkyl; $R^3R^4NSO_2N(R^5)$-$C_{1-6}$alkyl; aryl-$C_{1-6}$alkyl; aryl-$C(=O)$-$C_{1-6}$alkyl; heterocyclyl-$C_{1-6}$alkyl; heterocyclyl-$C(=O)$-$C_{1-6}$alkyl; substituted aryl-$C_{1-6}$alkyl; substituted aryl-$C(=O)$-$C_{1-6}$alkyl; substituted heterocyclyl-$C_{1-6}$alkyl; substituted heterocyclyl-$C(=O)$-$C_{1-6}$alkyl; and $C_{1-10}$hydrocarbylamino;

$R^2$ is selected from $C_{1-6}$alkyl, substituted $C_{1-6}$alkyl, $C_{2-6}$alkenyl, substituted $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, substituted $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl, substituted $C_{3-6}$cycloalkyl, aryl, substituted aryl, and $C_{5-6}$heteroaryl, and substituted $C_{5-6}$heteroaryl;

$R^3$, $R^4$ and $R^5$ are independently selected from -H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, and a divalent $C_{1-6}$group that together with another divalent $C_{1-6}$group forms a portion of a ring;

X is a $C_{1-10}$ divalent group that separates groups connected thereto by one or two atoms;

Ar is a $C_{4-12}$ divalent aromatic group; and

Y is selected from –CH= and –N=.

Claim 2. (original) The compound as claimed in claim 1, wherein

$R^{F1}$ and $R^{F2}$ are independently $C_{1-6}$alkyl substituted by one or more groups selected from -F, -Cl, -Br, $-NO_2$, -CN, -OH, -CHO, -C(=O)-R' and -OR', wherein R' is a $C_{1-3}$alkyl.

Claim 3. (original) The compound as claimed in claim 1, wherein

$R^{F1}$ and $R^{F2}$ are independently selected from $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CHFCF_3$, $-CHFCHF_2$, $-CHFCH_2F$, $-CF_2CF_3$, $-CF_2CH_3$, $-CF_2CH_2F$, $-CF_2CHF_2$, $-CF_3$, $-CH_2CCl_3$, $-CH_2CHCl_2$, $-CH_2CBr_3$, $-CH_2CHBr_2$, $-CH_2NO_2$, $-CH_2CH_2NO_2$, $-CH_2CN$, $-CH_2CH_2CN$, and $-CH_2CH_2OCH_3$.

Claim 4. (original) The compound as claimed in claim 1, wherein $R^{F1}$ and $R^{F2}$ are independently $C_{1-6}$ groups that comprise at least 30% fluorine by weight and Z is O=.

Claim 5. (original) The compound as claimed in claim 1, wherein $R^1$ is selected from $C_{1-10}$ alkyl; $C_{1-10}$alkyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkenyl; $C_{2-10}$alkenyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkynyl; $C_{2-10}$alkynyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $R^3R^4N$-$C_{1-6}$alkyl; $R^3R^4NC(=O)$-$C_{1-6}$alkyl; $R^3O$-$C_{1-6}$ alkyl; $R^3OC(=O)$-$C_{1-6}$alkyl; $R^3C(=O)$-$C_{1-6}$alkyl; $R^3C(=O)NR^3$-$C_{1-6}$alkyl; $R^3R^4NSO_2$-$C_{1-6}$alkyl; $R^3CSO_2N(R^4)$-$C_{1-6}$alkyl; $R^3R^4NC(=O)N(R^5)$-$C_{1-6}$alkyl; $R^3R^4NSO_2N(R^5)$-$C_{1-6}$alkyl; aryl-$C_{1-6}$alkyl; aryl-C(=O)-$C_{1-6}$alkyl; heterocyclyl-$C_{1-6}$alkyl; heterocyclyl-C(=O)-$C_{1-6}$alkyl; substituted aryl-$C_{1-6}$alkyl; substituted aryl-C(=O)-$C_{1-6}$alkyl; substituted heterocyclyl-$C_{1-6}$alkyl; substituted heterocyclyl-C(=O)-$C_{1-6}$alkyl; and $C_{1-10}$hydrocarbylamino;

$R^2$ is selected from $C_{1-6}$alkyl, $C_{1-6}$alkyl substituted by at least one fluorine, $C_{2-6}$alkenyl, $C_{2-6}$alkenyl substituted by at least one fluorine, $C_{2-6}$alkynyl, $C_{2-6}$alkynyl substituted by at least one fluorine, $C_{3-6}$cycloalkyl, substituted $C_{3-6}$cycloalkyl, aryl, substituted aryl, and $C_{5-6}$heteroaryl, and substituted $C_{5-6}$heteroaryl;

$R^3$, $R^4$ and $R^5$ are independently selected from -H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, and a divalent $C_{1-6}$group that together with another divalent $C_{1-6}$group forms a portion of a ring; and

X is selected from $-NR^6-$, -C(=O)-, $-CH_2-CH_2-$, -CH=CH-, -O-, $-C(R^6)(R^7)-$, and $-S(O)_n-$, wherein n is 0, 1 or 2, wherein $R^6$ and $R^7$ are independently $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{1-6}$alkoxy, -OH, or -H.

Claim 6. (original) A compound according to Claim 1,
wherein:

$R^1$ is selected from $C_{1-8}$alkyl; $C_{2-8}$alkenyl; $C_{2-8}$ alkynyl; aryl-$C_{1-6}$alkyl; aryl-$C_{1-6}$alkyl with the aryl substituted by at least one group selected from $C_{1-6}$alkyl, acetoxymethyl, nitro and halogen; $R^8R^9NC_{1-6}$alkyl; $R^8OC_{1-6}$alkyl; cycloalkyl-$C_{1-6}$alkyl; heterocycloalkyl-$C_{1-6}$alkyl; heterocycloalkyl-$C_{1-6}$alkyl with the heterocylcoalkyl thereof substituted by at least one group selected from $C_{1-8}$alkyl, acetoxymethyl, nitro and halogen; $C_{1-6}$alkylaryl; $C_{1-6}$alkyl-C(=O)-; $C_{6-8}$aryl-C(=O)-; $C_{4-8}$heteroaryl-C(=O)-; heteroaryl-$C_{1-6}$alkyl; heteroaryl-$C_{1-6}$alkyl with the heteroaryl thereof substituted by at least one group selected from $C_{1-6}$alkyl, acetoxymethyl, nitro and halogen; and $R^NC_{1-6}$alkyl;

$R^2$ is selected from $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $C_{3-6}$cycloalkyl, $-CH_2CF_3$, $-CHF_2$, $-CF_3$ and aryl;

$R^N$ is an oxidized pyridyl wherein the nitrogen atom on the pyridyl ring is in an oxidized state ($N^+$-$O^-$);

Ar is selected from an arylene; an heteroarylene; an arylene substituted by at least one group selected from $C_{1-6}$alkyl, halogen, trifluoromethyl, cyano, nitro, hydroxy and $C_{1-6}$alkoxy; and an heteroarylene substituted by at least one group selected from $C_{1-6}$alkyl, halogen, trifluoromethyl, cyano, nitro, hydroxy and $C_{1-6}$alkoxy; and

$R^8$ and $R^9$ are independently selected from -H and $C_{1-6}$alkyl.

Claim 7. (original) The compound according to claim 6,

wherein the arylene is *para*-arylene; and the heteroarylene is selected from six-membered ring *para*-heteroarylene and five-membered ring *meta*-heteroarylene.

Claim 8. (original) A compound according to Claim 1, wherein:

$R^1$ is selected from ethyl, propyl, allyl, isopentyl, benzyl, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, 3-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, N-methyl-3-pyrrolidylmethyl, 2-piperidylmethyl, 3-piperidylmethyl, 4-piperidylmethyl, N-methyl-2-piperidylmethyl, N-methyl-3-piperidylmethyl, N-methyl-4-piperidylmethyl, 3-thienylmethyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 2-tetrahydropyranylmethyl, 3-tetrahydropyranylmethyl, 4-tetrahydropyranylmethyl, (2-nitrothiophene-5-yl)methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furanyl)methyl, (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);

$R^2$ is selected from $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CF_3$, $CF_3$, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl;

$R^{F1}$ and $R^{F2}$ are $-CH_2CF_3$ and Z is O=;

Ar is selected from a *para*-arylene; a *para*-arylene substituted with $C_{1-6}$alkyl, halogen, trifluoromethyl, cyano, nitro, hydroxy and $C_{1-6}$alkoxy; a six-membered ring *para*-heteroarylene; and a six-membered ring *para*-heteroarylene substituted with a group selected from $C_{1-6}$alkyl, halogen, trifluoromethyl, cyano, nitro, hydroxy and $C_{1-6}$alkoxy.

Claim 9. (original) A compound according to Claim 1, wherein:

$R^{F1}$ and $R^{F2}$ are $-CH_2CF_3$, and Z is O=;

$R^2$ is $-CH_2CH_3$;

Ar is selected from *para*-phenylene and *para*-pyridylene; and

X is selected from $-CH_2-$ and $-CH(CH_3)-$.

Claim 10. (original) A compound according to claim 1, wherein said compound is selected from:

2-[(4-Ethoxyphenyl)methyl]-1-(3-methylbutyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-(2-furanylmethyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[(2*S*)-2-pyrrolidinylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[(2*R*)-2-pyrrolidinylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-ethoxyphenyl)methyl]-1-(4-pyridinylmethyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[1-(4-Ethoxyphenyl)ethyl]-1-(4-pyridinylmethyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[(tetrahydro-2*H*-pyran-4-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[[(2*R*)-tetrahydro-2-furanyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[[(2*S*)-tetrahydro-2-furanyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[(tetrahydro-2*H*-pyran-2-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[(2R)-2-piperidinylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxy-2-pyridyl)methyl]-1-[(tetrahydro-2*H*-pyran-4-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxy-2-pyridinyl)methyl]-1-(3-methylbutyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[[(2*R*)-1-methyl-2-pyrrolidinyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(4-Ethoxyphenyl)methyl]-1-[[(2*R*)-1-methyl-2-piperidinyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxy-2-pyridinyl)methyl]-1-[(2*R*)-2-pyrrolidinylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[1-(4-Ethoxyphenyl)ethyl]-1-[(2*R*)-2-pyrrolidinylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxy-2-pyridinyl)methyl]-1-[[(2*R*)-1-methyl-2-piperidinyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxy-2-pyridinyl)methyl]-1-[[(2*R*)-1-methyl-2-pyrrolidinyl]methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclobutylmethyl)-2-(4-ethoxybenzyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclobutylmethyl)-2-[(5-ethoxypyridin-2-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclopentylmethyl)-2-[(5-ethoxypyridin-2-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-(4-Ethoxybenzyl)-1-[(2*S*)-piperidin-2-ylmethyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxypyridin-2-yl)methyl]-1-(3-furylmethyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxypyridin-2-yl)methyl]-1-(3-thienylmethyl)-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclohexylmethyl)-2-[(5-ethoxypyridin-2-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

1-(Cyclohexylmethyl)-2-[(5-isopropoxypyridin-2-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-(4-Ethoxybenzyl)-1-[(4-methylmorpholin-3-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-[(5-Ethoxypyridin-2-yl)methyl]-1-[(4-methylmorpholin-3-yl)methyl]-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-(4-Ethoxybenzyl)-1-{[(2*S*)-1-methylpiperidin-2-yl]methyl}-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

2-(4-Isopropoxybenzyl)-1-{[(2*R*)-1-methylpiperidin-2-yl]methyl}-*N*,*N*-bis(2,2,2-trifluoroethyl)-1*H*-benzimidazole-5-carboxamide;

and pharmaceutically acceptable salts thereof.

Claims 11-14. (canceled)

Claim 15. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1~~-10~~ and a pharmaceutically acceptable carrier.

Claim 16. (currently amended) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to ~~any one of~~ claims 1~~-10~~.

Claim 17. (original) A method of producing a compound comprising the step of reacting a compound represented by formula (II) with $R^2OArXCOA$:



(II)

wherein

$R^{F1}$ and $R^{F2}$ are independently electron-withdrawing groups;

Z is selected from O= and S=;

$R^1$ is selected from $C_{1-10}$ alkyl; $C_{1-10}$alkyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkenyl; $C_{2-10}$alkenyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $C_{2-10}$alkynyl; $C_{2-10}$alkynyl substituted by at least one of halogen, cyano, acetoxymethyl and nitro; $R^3R^4N$-$C_{1-6}$alkyl; $R^3R^4NC(=O)$-$C_{1-6}$alkyl; $R^3O$-$C_{1-6}$ alkyl; $R^3OC(=O)$-$C_{1-6}$alkyl; $R^3C(=O)$-$C_{1-6}$alkyl; $R^3C(=O)NR^3$-$C_{1-6}$alkyl; $R^3R^4NSO_2$-$C_{1-6}$alkyl; $R^3CSO_2N(R^4)$-$C_{1-6}$alkyl; $R^3R^4NC(=O)N(R^5)$-$C_{1-6}$alkyl; $R^3R^4NSO_2N(R^5)$-$C_{1-6}$alkyl; aryl-$C_{1-6}$alkyl; aryl-$C(=O)$-$C_{1-6}$alkyl; heterocyclyl-$C_{1-6}$alkyl; heterocyclyl-$C(=O)$-$C_{1-6}$alkyl; substituted aryl-$C_{1-6}$alkyl; substituted aryl-$C(=O)$-$C_{1-6}$alkyl; substituted heterocyclyl-$C_{1-6}$alkyl; substituted heterocyclyl-$C(=O)$-$C_{1-6}$alkyl; and $C_{1-10}$hydrocarbylamino;

$R^2$ is selected from $C_{1-6}$alkyl, substituted $C_{1-6}$alkyl, $C_{2-6}$alkenyl, substituted $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, substituted $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl, substituted $C_{3-6}$cycloalkyl, aryl, substituted aryl, and $C_{5-6}$heteroaryl, and substituted $C_{5-6}$heteroaryl;

$R^3$, $R^4$ and $R^5$ are independently selected from -H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, and a divalent $C_{1-6}$group that together with another divalent $C_{1-6}$group forms a portion of a ring;

X is a $C_{1-10}$divalent group that separates groups connected thereto by one or two atoms;

A is selected from –OH, -Cl, -Br, and –I;

Ar is a $C_{4-12}$ divalent aromatic group; and

Y is selected from –CH= and –N=.

Claim 18. (original) A method of producing a compound comprising the step of reacting a compound represented by formula (III) with formaldehyde:



(III)

wherein

r and s are selected from 0, 1 and 2;

$R^{10}$ is selected from $C_{1-6}$alkylene, -O-, and $-NR^{11}$-, wherein $R^{11}$ is a $C_{1-6}$alkyl;

$R^{F1}$ and $R^{F2}$ are independently electron-withdrawing groups;

X is a $C_{1-10}$divalent group that separates groups connected thereto by one or two atoms;

Ar is a $C_{4-12}$divalent aromatic group;

$R^2$ is selected from $C_{1-6}$alkyl, substituted $C_{1-6}$alkyl, $C_{2-6}$alkenyl, substituted $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, substituted $C_{2-6}$alkynyl, $C_{3-6}$cycloalkyl, substituted $C_{3-6}$cycloalkyl, aryl, substituted aryl, and $C_{5-6}$heteroaryl, and substituted $C_{5-6}$heteroaryl; and

Y is selected from –CH= and –N=.

Claim 19. (New) A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier.

Claim 20. (New) A pharmaceutical composition comprising a compound according to claim 9 and a pharmaceutically acceptable carrier.

Claim 21. (New) A pharmaceutical composition comprising a compound according to claim 10 and a pharmaceutically acceptable carrier.

Claim 22. (new) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 8.

Claim 23. (new) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 9.

Claim 24. (new) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 10.